These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 24806899)

  • 21. Gas chromatography/mass spectrometric analysis of urinary nucleosides in cancer patients; potential of modified nucleosides as tumour markers.
    Langridge JI; McClure TD; el-Shakawi S; Fielding A; Schram KH; Newton RP
    Rapid Commun Mass Spectrom; 1993 Jun; 7(6):427-34. PubMed ID: 8329765
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer biomarker discovery: Opportunities and pitfalls in analytical methods.
    Issaq HJ; Waybright TJ; Veenstra TD
    Electrophoresis; 2011 Apr; 32(9):967-75. PubMed ID: 21449066
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer biomarkers: knowing the present and predicting the future.
    Chatterjee SK; Zetter BR
    Future Oncol; 2005 Feb; 1(1):37-50. PubMed ID: 16555974
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical proteomics and mass spectrometry profiling for cancer detection.
    Solassol J; Jacot W; Lhermitte L; Boulle N; Maudelonde T; Mangé A
    Expert Rev Proteomics; 2006 Jun; 3(3):311-20. PubMed ID: 16771703
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Capillary electrophoresis-mass spectrometry, an attractive tool for drug bioanalysis and biomarker discovery.
    Servais AC; Crommen J; Fillet M
    Electrophoresis; 2006 Jul; 27(13):2616-29. PubMed ID: 16817163
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Applications of mass spectrometry to metabolomics and metabonomics: detection of biomarkers of aging and of age-related diseases.
    Mishur RJ; Rea SL
    Mass Spectrom Rev; 2012; 31(1):70-95. PubMed ID: 21538458
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cancer proteomics.
    Tan HT; Lee YH; Chung MC
    Mass Spectrom Rev; 2012; 31(5):583-605. PubMed ID: 22422534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of bladder cancer in human urine by metabolomic profiling using high performance liquid chromatography/mass spectrometry.
    Issaq HJ; Nativ O; Waybright T; Luke B; Veenstra TD; Issaq EJ; Kravstov A; Mullerad M
    J Urol; 2008 Jun; 179(6):2422-6. PubMed ID: 18433783
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liquid chromatography tandem mass spectrometry study of urinary nucleosides as potential cancer markers.
    Struck W; Siluk D; Yumba-Mpanga A; Markuszewski M; Kaliszan R; Markuszewski MJ
    J Chromatogr A; 2013 Mar; 1283():122-31. PubMed ID: 23465127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Separation and identification of purine nucleosides in the urine of patients with malignant cancer by reverse phase liquid chromatography/electrospray tandem mass spectrometry.
    Li HY; Wang SM; Liu HM; Bu SS; Li J; Han D; Zhang MZ; Wu GY
    J Mass Spectrom; 2009 May; 44(5):641-51. PubMed ID: 19142897
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer diagnosis by breath analysis: what is the future?
    García-Muñoz RA; Morales V; Toledano A
    Bioanalysis; 2014 Sep; 6(18):2331-3. PubMed ID: 25384586
    [No Abstract]   [Full Text] [Related]  

  • 32. Simultaneous detection of six urinary pteridines and creatinine by high-performance liquid chromatography-tandem mass spectrometry for clinical breast cancer detection.
    Burton C; Shi H; Ma Y
    Anal Chem; 2013 Nov; 85(22):11137-45. PubMed ID: 24138137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mass spectrometric profiling of low-molecular-weight proteins.
    Rainer M; Sajdik C; Bonn GK
    Methods Mol Biol; 2013; 1023():83-95. PubMed ID: 23765620
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations.
    Verma M; Manne U
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):9-18. PubMed ID: 16829121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mass spectrometry-based "omics" technologies in cancer diagnostics.
    Zhang X; Wei D; Yap Y; Li L; Guo S; Chen F
    Mass Spectrom Rev; 2007; 26(3):403-31. PubMed ID: 17405143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Molecular diagnosis of neoplasms].
    Wilczyńska A; Siedlecki JA
    Med Wieku Rozwoj; 1999; 3(1):23-32. PubMed ID: 10910635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer. Developing molecular biomarkers for cancer.
    Ransohoff DF
    Science; 2003 Mar; 299(5613):1679-80. PubMed ID: 12637728
    [No Abstract]   [Full Text] [Related]  

  • 38. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome.
    Cho WC
    Expert Rev Proteomics; 2011 Feb; 8(1):1-4. PubMed ID: 21329422
    [No Abstract]   [Full Text] [Related]  

  • 39. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.
    Theodorescu D; Wittke S; Ross MM; Walden M; Conaway M; Just I; Mischak H; Frierson HF
    Lancet Oncol; 2006 Mar; 7(3):230-40. PubMed ID: 16510332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advances in separation science applied to metabonomics.
    Xiayan L; Legido-Quigley C
    Electrophoresis; 2008 Sep; 29(18):3724-36. PubMed ID: 18850642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.